Laura Brege
Laura Brege's purchase track record
Laura Brege has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/16/2024 | PCRX | $13K | +28.3% | +96.6% | +10.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta. Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.
Transaction History
| PCRX | ▲ Buy | Grant | 6,405 | $0 | 6/10/2026 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 8,107 | — | 5/29/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 15,509 | $1.2M | 9/11/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,491 | $112K | 9/11/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 17,000 | $255K | 9/11/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 6,163 | $0 | 6/11/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 14,446 | $315K | 6/4/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 5,703 | — | 5/29/2025 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,387 | — | 5/29/2025 | View on chart |
| PCRX | ▲ Buy | Open Market | 1,000 | $13K | 8/16/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 5,230 | $0 | 6/12/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,652 | — | 5/29/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 1,775 | $0 | 6/14/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 4,500 | $112K | 6/12/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 600 | $23K | 6/5/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 8,552 | — | 6/1/2023 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 7,000 | $209K | 4/3/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 7,000 | $285K | 4/3/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 12,500 | $213K | 1/12/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 12,500 | $228K | 1/12/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 1,160 | $0 | 6/8/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,391 | — | 6/7/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 3,059 | — | 6/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.